2024 World Conference on Lung Cancer (WCLC) - Posters-P4.17D.07 Temporal Improvements in Overall Survival in Metastatic Non-Small Cell Lung Cancer in the United States Since 2004

P4.17D.07 Temporal Improvements in Overall Survival in Metastatic Non-Small Cell Lung Cancer in the United States Since 2004

Back to course

Pdf Summary

The study examines the improvement in overall survival rates for patients with metastatic non-small cell lung cancer (mNSCLC) in the U.S. from 2004 to 2018, utilizing data from the SEER cancer registry. It highlights that advancements in targeted therapy (approved in 2003) and immunotherapy (approved in 2015) have contributed to survival improvements over time. The cohort consisted of 238,680 patients, with 118,829 receiving systemic therapy. The study found that overall survival increased across all patients and particularly for those treated with systemic therapy, who experienced a significant 43% reduction in mortality risk by 2018 compared to 2004.<br /><br />In the adjusted survival model, hazard ratios for each year showed gradual improvements with notable figures in systemic therapy recipients: 0.91 in 2010, 0.77 in 2014, and 0.57 in 2018, compared to 2004. Overall 24-month survival improved from 13% to 16% for all diagnosed patients and from 18% to 26% for those receiving systemic therapy. Projections suggest a further increase by 2024, with systemic therapy recipient survival expected to reach 33%.<br /><br />While these results demonstrate progress, the study emphasizes the ongoing need for new therapies to further enhance survival rates in mNSCLC. Notably, the study controlled for various factors such as age, sex, race, cancer stage, and other demographic influences using g-computation for robust analysis.<br /><br />Limitations include the absence of detailed data on specific therapies and genomic testing, and the exclusion of post-2019 data due to potential COVID-19 impacts. The study concludes that despite recent advancements, there is still a critical need for improved treatments to enhance patient outcomes in metastatic NSCLC.

Asset Subtitle

Yong Yuan

Meta Tag

Speaker Yong Yuan

Topic Global Health, Health Services & Health Economics

Keywords

metastatic non-small cell lung cancer

mNSCLC

survival rates

SEER cancer registry

targeted therapy

immunotherapy

systemic therapy

hazard ratios

g-computation

treatment advancements